Clinical trial
A Phase II Randomized Trial of Bicalutamide in Patients Receiving Intravesical BCG for Non-muscle Invasive Bladder Cancer
NCT05327647 is registered in ClinicalTrials.gov with CHU de Quebec-Universite Laval as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Randomized Trial of Bicalutamide in Patients Receiving Intravesical BCG for Non-muscle Invasive Bladder Cancer
- Lead sponsor
- CHU de Quebec-Universite Laval
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- June 23, 2022
- Completion date
- December 31, 2026
- Enrollment
- 160 (estimated)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.
non-muscle invasive bladder cancer